Regorafenib as Second-Line Versus Later-Line Therapy in Advanced Hepatocellular Carcinoma: A Multicenter Real-World Study with Exploratory Analysis of Prior Immune Checkpoint Inhibitor Exposure.
- DOI
- 10.1007/s11523-026-01252-x
- Published
- 2026 Sep 1
- Container
- Targeted oncology
- Publisher
- Not recorded
- Open access
- unknown
Credibility signals
limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1007/s11523-026-01252-x,
title = {Regorafenib as Second-Line Versus Later-Line Therapy in Advanced Hepatocellular Carcinoma: A Multicenter Real-World Study with Exploratory Analysis of Prior Immune Checkpoint Inhibitor Exposure.},
author = {Tak KY and Cho HS and Lee J and Yang K and Lee A and Han JW and Lee SK and Yang H and Nam H and Kim HY and Lee SW and Kim SH and Song DS and Song MJ and Kwon JH and Chang U and Nam SW and Kim CW and Jang JW and Bae SH and Lee HL and Sung PS},
year = {2026},
journal = {Targeted oncology},
doi = {10.1007/s11523-026-01252-x},
url = {https://doi.org/10.1007/s11523-026-01252-x}
}RIS
TY - JOUR TI - Regorafenib as Second-Line Versus Later-Line Therapy in Advanced Hepatocellular Carcinoma: A Multicenter Real-World Study with Exploratory Analysis of Prior Immune Checkpoint Inhibitor Exposure. AU - Tak KY AU - Cho HS AU - Lee J AU - Yang K AU - Lee A AU - Han JW AU - Lee SK AU - Yang H AU - Nam H AU - Kim HY AU - Lee SW AU - Kim SH AU - Song DS AU - Song MJ AU - Kwon JH AU - Chang U AU - Nam SW AU - Kim CW AU - Jang JW AU - Bae SH AU - Lee HL AU - Sung PS PY - 2026 JO - Targeted oncology DO - 10.1007/s11523-026-01252-x UR - https://doi.org/10.1007/s11523-026-01252-x ER -
APA
KY, T., HS, C., J, L., K, Y., A, L., JW, H., SK, L., H, Y., H, N., HY, K., SW, L., SH, K., DS, S., MJ, S., JH, K., U, C., SW, N., CW, K., JW, J., SH, B., HL, L., & PS, S. (2026). Regorafenib as Second-Line Versus Later-Line Therapy in Advanced Hepatocellular Carcinoma: A Multicenter Real-World Study with Exploratory Analysis of Prior Immune Checkpoint Inhibitor Exposure.. Targeted oncology. https://doi.org/10.1007/s11523-026-01252-x
Source records
- pubmed · retrieved 2026-09-26T03:09:39.500Z